Payment overview · 2025
General Payments
$1,505.58
96 reported records · 30 companies
Healthcare provider profile · identity verified
Glen J. Dasher, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STATESBORO, GA · NPI 1972684546
Verified facts
What the public records show
CMS Open Payments records show Glen J. Dasher, M.D. received $1,505.58 in general payments during 2025 across 96 reported records.
PFIZER INC. accounted for 11.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Kerendia, Mounjaro, Nexletol, Otezla, Ozempic, Shingrix, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 446 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 716 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 448 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 716 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $170.31 | 11.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $165.67 | 11.0% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.95 | 9.8% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $114.18 | 7.6% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $98.57 | 6.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.66 | 5.8% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $69.22 | 4.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.60 | 4.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.79 | 4.0% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $49.92 | 3.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.32 | 3.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.65 | 2.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.15 | 2.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.82 | 2.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.30 | 2.3% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $28.32 | 1.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.93 | 1.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $22.80 | 1.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.44 | 1.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.32 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.23 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.68 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.92 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.84 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.80 | 1.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.88 | 1.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.55 | 1.0% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $14.91 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.62 | 0.9% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $10.23 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,505.58 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $149.51 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $116.84 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $116.84 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $104.70 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $98.57 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.69 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $82.54 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $69.22 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.60 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.45 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.32 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $48.83 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.71 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.55 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.25 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.82 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.49 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $10.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 111 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 716 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 202 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 379 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 263 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 93 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
177 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
146 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
446 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
202 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
716 | 64 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
111 | 111 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
93 | 77 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
448 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
379 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
87 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
263 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
716 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2094 | 265 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1803 | 216 |
| Gabapentin | Gabapentin | 1518 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 1405 | 202 |
| Famotidine | Famotidine | 1386 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1356 | 164 |
| Losartan Potassium | Losartan Potassium | 1230 | 203 |
| Trazodone Hcl | Trazodone Hcl | 1101 | 139 |
| Potassium Chloride | Potassium Chloride | 993 | 136 |
| Omeprazole | Omeprazole | 979 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 946 | 196 |
| Lisinopril | Lisinopril | 935 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 898 | 191 |
| Furosemide | Furosemide | 864 | 116 |
| Escitalopram Oxalate | Escitalopram Oxalate | 847 | 92 |
| Carvedilol | Carvedilol | 733 | 88 |
| Donepezil Hcl | Donepezil Hcl | 725 | 68 |
| Eliquis | Apixaban | 716 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 716 | 116 |
| Hydrochlorothiazide | Hydrochlorothiazide | 628 | 98 |
| Ropinirole Hcl | Ropinirole Hcl | 624 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 607 | 58 |
| Sertraline Hcl | Sertraline Hcl | 602 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 570 | 94 |
| Hydralazine Hcl | Hydralazine Hcl | 532 | 78 |
| Simvastatin | Simvastatin | 525 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 498 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 460 | 71 |
| Jardiance | Empagliflozin | 448 | 38 |
| Montelukast Sodium | Montelukast Sodium | 447 | 78 |
| Myrbetriq | Mirabegron | 446 | 46 |
| Fenofibrate | Fenofibrate | 441 | 70 |
| Valsartan | Valsartan | 437 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 433 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 419 | 56 |
| Mirtazapine | Mirtazapine | 419 | 24 |
| Metformin Hcl | Metformin Hcl | 416 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 410 | 91 |
| Ezetimibe | Ezetimibe | 391 | 80 |
| Metformin Hcl Er | Metformin Hcl | 388 | 81 |
| Meloxicam | Meloxicam | 384 | 61 |
| Lorazepam | Lorazepam | 380 | 105 |
| Mounjaro | Tirzepatide | 379 | 59 |
| Olanzapine | Olanzapine | 372 | 14 |
| Tradjenta | Linagliptin | 365 | 34 |
| Levetiracetam | Levetiracetam | 359 | 12 |
| Alprazolam | Alprazolam | 354 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 336 | 64 |
| Sucralfate | Sucralfate | 325 | 49 |
| Fenofibrate | Fenofibrate Nanocrystallized | 323 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 322 | 115 |
| Buspirone Hcl | Buspirone Hcl | 309 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 307 | 38 |
| Aripiprazole | Aripiprazole | 294 | 15 |
| Allopurinol | Allopurinol | 290 | 52 |
| Memantine Hcl | Memantine Hcl | 276 | 26 |
| Tramadol Hcl | Tramadol Hcl | 270 | 88 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 264 | 81 |
| Ozempic | Semaglutide | 263 | 61 |
| Prednisone | Prednisone | 260 | 113 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 253 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 252 | 34 |
| Alendronate Sodium | Alendronate Sodium | 248 | 19 |
| Clonazepam | Clonazepam | 247 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 230 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 85 |
| Oxycodone Hcl | Oxycodone Hcl | 211 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 209 | 45 |
| Azithromycin | Azithromycin | 207 | 175 |
| Finasteride | Finasteride | 206 | 39 |
| Farxiga | Dapagliflozin Propanediol | 202 | 16 |
| Baclofen | Baclofen | 199 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 35 |
| Testosterone Cypionate | Testosterone Cypionate | 185 | 39 |
| Linzess | Linaclotide | 177 | 37 |
| Januvia | Sitagliptin Phosphate | 176 | 22 |
| Methocarbamol | Methocarbamol | 172 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 166 | 30 |
| Fluconazole | Fluconazole | 156 | 90 |
| Divalproex Sodium | Divalproex Sodium | 155 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 151 | 27 |
| Ibuprofen | Ibuprofen | 151 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 147 | 67 |
| Synthroid | Levothyroxine Sodium | 146 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 145 | 47 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 142 | 34 |
| Levofloxacin | Levofloxacin | 142 | 75 |
| Xarelto | Rivaroxaban | 141 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 139 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 139 | 33 |
| Primidone | Primidone | 137 | 11 |
| Bupropion Xl | Bupropion Hcl | 134 | 28 |
| Celecoxib | Celecoxib | 133 | 27 |
| Sevelamer Carbonate | Sevelamer Carbonate | 131 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 131 | 23 |
| Pregabalin | Pregabalin | 130 | 40 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 129 | 21 |
| Chlorthalidone | Chlorthalidone | 127 | 17 |
| Estradiol | Estradiol | 124 | 30 |
| Spironolactone | Spironolactone | 121 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 39 |
| Glipizide Er | Glipizide | 119 | 33 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 118 | 15 |
| Clonidine Hcl | Clonidine Hcl | 118 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 117 | 76 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 116 | 15 |
| Ondansetron Odt | Ondansetron | 115 | 55 |
| Bupropion Hcl Sr | Bupropion Hcl | 113 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 112 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 111 | 111 |
| Azelastine Hcl | Azelastine Hcl | 111 | 56 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 82 |
| Calcitriol | Calcitriol | 110 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 106 | 24 |
| Meclizine Hcl | Meclizine Hcl | 105 | 38 |
| Propranolol Hcl | Propranolol Hcl | 105 | 12 |
| Glycopyrrolate | Glycopyrrolate | 104 | suppressed |
| Nystatin | Nystatin | 104 | 55 |
| Nifedipine Er | Nifedipine | 103 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 38 |
| Risperidone | Risperidone | 102 | 17 |
| Atenolol | Atenolol | 99 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 95 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 93 | 77 |
| Temazepam | Temazepam | 93 | 27 |
| Glipizide | Glipizide | 88 | suppressed |
| Entresto | Sacubitril/Valsartan | 87 | suppressed |
| Novolog Flexpen | Insulin Aspart | 87 | 17 |
| Topiramate | Topiramate | 85 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 50 |
| Valacyclovir | Valacyclovir Hcl | 83 | 36 |
| Glimepiride | Glimepiride | 81 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 78 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 67 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 76 | 15 |
| Benazepril Hcl | Benazepril Hcl | 73 | 15 |
| Cephalexin | Cephalexin | 72 | 47 |
| Megestrol Acetate | Megestrol Acetate | 72 | 29 |
| Morphine Sulfate Er | Morphine Sulfate | 71 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 70 | 16 |
| Methylprednisolone | Methylprednisolone | 70 | 53 |
| Mupirocin | Mupirocin | 70 | 51 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 40 |
| Clonidine | Clonidine | 65 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 64 | suppressed |
| Lansoprazole | Lansoprazole | 64 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 64 | suppressed |
| Dexamethasone | Dexamethasone | 62 | 58 |
| Promethazine Hcl | Promethazine Hcl | 62 | 32 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 62 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 62 | 12 |
| Bupropion Hcl | Bupropion Hcl | 60 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 58 | 18 |
| Lamotrigine | Lamotrigine | 57 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 55 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 55 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 18 |
| Amantadine | Amantadine Hcl | 53 | suppressed |
| Digoxin | Digoxin | 53 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 53 | suppressed |
| Amoxicillin | Amoxicillin | 52 | 32 |
| Ibandronate Sodium | Ibandronate Sodium | 52 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 51 | suppressed |
| Haloperidol | Haloperidol | 49 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 49 | 16 |
| Kerendia | Finerenone | 48 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 47 | suppressed |
| Gemtesa | Vibegron | 47 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 45 | suppressed |
| Belsomra | Suvorexant | 44 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 44 | suppressed |
| Lactulose | Lactulose | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Metronidazole | Metronidazole | 42 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 25 |
| Diazepam | Diazepam | 40 | 12 |
| Hydrocortisone | Hydrocortisone | 40 | 23 |
| Levemir Flexpen | Insulin Detemir | 40 | 12 |
| Naproxen | Naproxen | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Cefdinir | Cefdinir | 39 | 25 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 39 | 24 |
| Scopolamine | Scopolamine | 39 | suppressed |
| Sotalol | Sotalol Hcl | 39 | suppressed |
| Telmisartan | Telmisartan | 39 | suppressed |
| Folic Acid | Folic Acid | 38 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 38 | 19 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | 11 |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Armour Thyroid | Thyroid,pork | 36 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 36 | 36 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Colchicine | Colchicine | 36 | 15 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Rybelsus | Semaglutide | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 35 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 35 | suppressed |
| Progesterone | Progesterone, Micronized | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Methotrexate | Methotrexate Sodium | 32 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | 12 |
| Cilostazol | Cilostazol | 29 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Galantamine Er | Galantamine Hbr | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 27 | suppressed |
| Premarin | Estrogens, Conjugated | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | 12 |
| Lidocaine | Lidocaine | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | 11 |
| Roflumilast | Roflumilast | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 22 | 20 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 22 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 20 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 19 | 12 |
| Fentanyl | Fentanyl | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Linezolid | Linezolid | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 17 |
| Unifine Pentips | Pen Needle, Diabetic | 19 | 11 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nexletol | Bempedoic Acid | 17 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | 13 |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Alprazolam Er | Alprazolam | 14 | suppressed |
| Armodafinil | Armodafinil | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alprazolam Xr | Alprazolam | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Tolvaptan | Tolvaptan | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,505.58 · 96 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Azstarys, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Flector, General - Pain Management, IBSRELA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, Licart, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, TONMYA, The Cologuard Plus Collection Kit, Tirosint, Tymlos, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error